What is Advanced Accelerator Applications?
Founded in 2002 and headquartered in Saint-Genis-Pouilly, France, Advanced Accelerator Applications is a prominent pharmaceutical group dedicated to the field of nuclear medicine. The company's operations span all three key segments of nuclear medicine, focusing on the diagnosis and treatment of serious conditions across oncology, neurology, cardiology, and infectious and inflammatory diseases. Their comprehensive approach aims to advance patient care through innovative radiopharmaceutical solutions.
How much funding has Advanced Accelerator Applications raised?
Advanced Accelerator Applications has raised a total of $131.4M across 2 funding rounds:
Unspecified
$56.4M
Stock Offering
$75M
Unspecified (2014): $56.4M with participation from HBM Healthcare Investments
Stock Issuance/Offering (2015): $75M, investors not publicly disclosed
Key Investors in Advanced Accelerator Applications
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market, driven by demographic trends, medical advancements, and increasing demand for innovative therapies.
What's next for Advanced Accelerator Applications?
The recent major strategic investment in Advanced Accelerator Applications suggests a trajectory focused on scaling operations, expanding research and development initiatives, and potentially broadening its market reach. This capital infusion is likely to accelerate the development of new diagnostic and therapeutic agents, further solidifying its leadership in the nuclear medicine sector. The company's continued focus on critical disease areas indicates a commitment to addressing unmet medical needs through advanced pharmaceutical technologies.
See full Advanced Accelerator Applications company page
